Brendon Neuen

Associate Professor Brendon Neuen is Lead Global Clinical Trialist at The George Institute for Global Health, and Staff Specialist Nephrologist, Director of Kidney Trials, at Royal North Shore Hospital. He is the Co-Chair of SMART-C (SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium; www.SMART-C.net), Director of the CLARITY-IgAN Consortium (Collaborative Longitudinal Assessment of Randomised Interventions and Therapies; www.CLARITY-IgAN.org) and holds senior leadership roles in multiple global, late-phase drug registration trials evaluating therapies to prevent kidney failure and cardiovascular disease.

His research has informed more than 30 clinical practice guidelines and consensus statements, and he is actively involved in the development of national and international standards, including for KDIGO and the American Society of Nephrology. A/Prof Neuen has authored over 175 peer-reviewed publications, including works in the New England Journal of Medicine, The Lancet, JAMA, and Nature Medicine. He serves on the editorial boards for flagship journals of the European Renal Association and the American Diabetes Association.

A/Prof Neuen studied medicine at James Cook University (First Class Honours, Academic Medal), holds a Masters in Global Health from the University of Oxford (Clarendon Scholar, top-ranked dissertation), a PhD from UNSW (NHMRC funded), and completed his Postdoctoral Fellowship at Harvard Medical School. A Fellow of both the Royal Australasian College of Physicians and the American Society of Nephrology, his work is supported by the NHMRC, Ramaciotti Foundation and philanthropic sources, and has been recognized through awards including the Royal Society of New South Wales Ida Browne Medal and the American Heart Association's Paul Dudley White International Scholar Award.